Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy (Q79198818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Sara Mariani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Massimo Massaia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

S Battaglio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

C Di Bello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

F Fiore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

M Foglietta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A Pileri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

M Boccadoro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

139-145

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14574332%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403181

20 December 2019

exact match

0 references

cites work

Diagnosis, prognosis, and standard treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

1 reference

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Ma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Optimizing dendritic cell-based immunotherapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403181

7 January 2021